Browse AOX1

Summary
SymbolAOX1
Namealdehyde oxidase 1
Aliases AO; azaheterocycle hydroxylase; Aldehyde oxidase
Chromosomal Location2q33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm
Domain PF01315 Aldehyde oxidase and xanthine dehydrogenase
PF02738 Molybdopterin-binding domain of aldehyde dehydrogenase
PF03450 CO dehydrogenase flavoprotein C-terminal domain
PF00941 FAD binding domain in molybdopterin dehydrogenase
PF00111 2Fe-2S iron-sulfur cluster binding domain
PF01799 [2Fe-2S] binding domain
Function

Oxidase with broad substrate specificity, oxidizing aromatic azaheterocycles, such as N1-methylnicotinamide, N-methylphthalazinium and phthalazine, as well as aldehydes, such as benzaldehyde, retinal, pyridoxal, and vanillin. Plays a key role in the metabolism of xenobiotics and drugs containing aromatic azaheterocyclic substituents. Participates in the bioactivation of prodrugs such as famciclovir, catalyzing the oxidation step from 6-deoxypenciclovir to penciclovir, which is a potent antiviral agent. Is probably involved in the regulation of reactive oxygen species homeostasis. May be a prominent source of superoxide generation via the one-electron reduction of molecular oxygen. Also may catalyze nitric oxide (NO) production via the reduction of nitrite to NO with NADH or aldehyde as electron donor. May play a role in adipogenesis.

> Gene Ontology
 
Biological Process GO:0006144 purine nucleobase metabolic process
GO:0006145 purine nucleobase catabolic process
GO:0006766 vitamin metabolic process
GO:0006767 water-soluble vitamin metabolic process
GO:0009112 nucleobase metabolic process
GO:0009115 xanthine catabolic process
GO:0019439 aromatic compound catabolic process
GO:0042816 vitamin B6 metabolic process
GO:0044270 cellular nitrogen compound catabolic process
GO:0046110 xanthine metabolic process
GO:0046113 nucleobase catabolic process
GO:0046700 heterocycle catabolic process
GO:0072523 purine-containing compound catabolic process
GO:0072524 pyridine-containing compound metabolic process
GO:0072593 reactive oxygen species metabolic process
GO:1901361 organic cyclic compound catabolic process
GO:1901565 organonitrogen compound catabolic process
Molecular Function GO:0004031 aldehyde oxidase activity
GO:0004854 xanthine dehydrogenase activity
GO:0005506 iron ion binding
GO:0009055 electron carrier activity
GO:0016614 oxidoreductase activity, acting on CH-OH group of donors
GO:0016623 oxidoreductase activity, acting on the aldehyde or oxo group of donors, oxygen as acceptor
GO:0016725 oxidoreductase activity, acting on CH or CH2 groups
GO:0016726 oxidoreductase activity, acting on CH or CH2 groups, NAD or NADP as acceptor
GO:0016903 oxidoreductase activity, acting on the aldehyde or oxo group of donors
GO:0043546 molybdopterin cofactor binding
GO:0048037 cofactor binding
GO:0050660 flavin adenine dinucleotide binding
GO:0050662 coenzyme binding
GO:0051287 NAD binding
GO:0051536 iron-sulfur cluster binding
GO:0051537 2 iron, 2 sulfur cluster binding
GO:0051540 metal cluster binding
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa04630 Jak-STAT signaling pathway
hsa00280 Valine, leucine and isoleucine degradation
hsa00350 Tyrosine metabolism
hsa00380 Tryptophan metabolism
hsa00750 Vitamin B6 metabolism
hsa00760 Nicotinate and nicotinamide metabolism
hsa00830 Retinol metabolism
hsa00982 Drug metabolism - cytochrome P450
hsa01100 Metabolic pathways
Reactome R-HSA-1430728: Metabolism
R-HSA-196854: Metabolism of vitamins and cofactors
R-HSA-196849: Metabolism of water-soluble vitamins and cofactors
R-HSA-964975: Vitamins B6 activation to pyridoxal phosphate
Summary
SymbolAOX1
Namealdehyde oxidase 1
Aliases AO; azaheterocycle hydroxylase; Aldehyde oxidase
Chromosomal Location2q33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between AOX1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolAOX1
Namealdehyde oxidase 1
Aliases AO; azaheterocycle hydroxylase; Aldehyde oxidase
Chromosomal Location2q33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of AOX1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolAOX1
Namealdehyde oxidase 1
Aliases AO; azaheterocycle hydroxylase; Aldehyde oxidase
Chromosomal Location2q33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of AOX1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.0680.923
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.2750.818
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.0520.952
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.3920.507
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.9330.617
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.2880.898
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.7630.325
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.6150.626
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.7310.632
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.0240.99
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.7480.76
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.7690.0105
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of AOX1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.107.10.452
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103100101
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277311.16.84.30.443
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275911.18.52.60.702
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211714.35.98.40.613
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131115.49.16.31
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.33.71.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.57.7-3.21
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 111307.7-7.71
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 51208.3-8.31
Summary
SymbolAOX1
Namealdehyde oxidase 1
Aliases AO; azaheterocycle hydroxylase; Aldehyde oxidase
Chromosomal Location2q33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of AOX1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolAOX1
Namealdehyde oxidase 1
Aliases AO; azaheterocycle hydroxylase; Aldehyde oxidase
Chromosomal Location2q33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of AOX1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by AOX1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolAOX1
Namealdehyde oxidase 1
Aliases AO; azaheterocycle hydroxylase; Aldehyde oxidase
Chromosomal Location2q33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of AOX1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolAOX1
Namealdehyde oxidase 1
Aliases AO; azaheterocycle hydroxylase; Aldehyde oxidase
Chromosomal Location2q33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of AOX1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolAOX1
Namealdehyde oxidase 1
Aliases AO; azaheterocycle hydroxylase; Aldehyde oxidase
Chromosomal Location2q33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between AOX1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolAOX1
Namealdehyde oxidase 1
Aliases AO; azaheterocycle hydroxylase; Aldehyde oxidase
Chromosomal Location2q33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting AOX1 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting AOX1.
ID Name Drug Type Targets #Targets
DB03516EniluracilSmall MoleculeAOX1, DPYD, XDH3